Videos | Bringing pharma’s top innovators to your screen

Sales & Marketing

Interview with Craig Ackerman Reuters at Pharma USA 2026

Biotech is back, with Craig Ackerman

In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.

R&D

Interview at LSX 2026 with Alexander Gebauer

LSX2026: On a therapeutic vision for ocular disease, with Al...

Alexander Gebauer, co-founder & executive chairman of Galimedix Therapeutics, discusses transforming treatment of major neurodegenerative eye diseases

Patients

Interview at LSX 2026 with Hans Schambye

LSX2026: On promise and patience, with Hans Schambye

At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.

Market Access

Interview with Marjorie Sidhoum at BIO Europe 2026

BIO-Europe Spring 2026: In conversation with Marjorie Sidhou...

Marjorie Sidhoum, vice president of business development & corporate communication at Kainova Therapeutics, discusses their immuno-oncology pipeline.

Patients

Interview with Phil Johnson at Pharma US 26

Using patient data to fill in GLP-1 blind spots, with Phil J...

At Reuters Pharma USA, Evidation Health's Phil Johnson talks about what pharma needs to know about their GLP-1 patients and how better data can help.

R&D

JP Morgan 2024 – Katherine Stueland

Diagnostics can be a neglected part of the treatment paradigm, but it’s hugely important for connecting patients with the right treatments.

R&D

JP Morgan 2024 – Gene Kinney

Back at JP Morgan 2024, editor-in-chief Jonah Comstock caught u

R&D

Jonah Comstock and Frank Gleeson at JP Morgan

JP Morgan 2024 – Frank Gleeson

In this brief dispatch from JP Morgan, Editor in Chief Jonah Comstock grabs a few minutes with Frank Gleeson, CEO of Satellos Bioscience.

Sales & Marketing

Biotech is back, with Craig Ackerman

In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.

Sales & Marketing

Interview at JPM26 with Helen Sabzevari and Greg Skalicky

Rewiring commercialisation to meet the moment, with Helen Sa...

At the Informa Biotech Showcase at JPM2026, EVERSANA President Greg Skalicky and Helen Sabzevari, CEO of Precigen, discuss new commercialisation.

Digital

Inizio Ignite, STEM AI video feature image

STEM AI: Delivering intelligent data-led HCP interactions

In a new sponsored video, pharmaphorum spoke with experts from STEM, an Inizio Ignite company, about STEM AI

Digital

Cracking the code: How European biotechs can win in the US m...

At Frontiers Health 2025, Mike Ryan, General Manager Europe at EVERSANA, tackled one of the most pressing questions for emerging pharma and biotech...

Market Access

BIO-Europe Spring 2026: In conversation with Marjorie Sidhou...

Marjorie Sidhoum, vice president of business development & corporate communication at Kainova Therapeutics, discusses their immuno-oncology pipeline.

Market Access

Consolidating data strategy for global success: Insights fro...

At Frontiers Health 2025, Drew McCormick, Head of Data and Analytics at EVERSANA, emphasised a critical truth: data strategy is launch strategy.

Oncology

Interview with Vicky Brown at Pharma USA 2026

Hernexeos and what’s next, with Vicky Brown

At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent US approval for Hernexeos in NSCLC.

Oncology

A cancer treatment modality that prioritises QoL, with Ben Z...

Immuneering's Ben Zeskind explains how, by focusing on quality of life as well as quantity, they've created a drug for pancreatic cancer.

Oncology

Engineering “smarter” cells, with Tim Lu

Senti Bio's Tim Lu discusses “logic-gated” cells, which have multiple receptors allowing them to attack cancer cells while leaving healthy cells alone

Patients

LSX2026: On promise and patience, with Hans Schambye

At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.

Patients

Using patient data to fill in GLP-1 blind spots, with Phil J...

At Reuters Pharma USA, Evidation Health's Phil Johnson talks about what pharma needs to know about their GLP-1 patients and how better data can help.

Patients

Interview at JPM26 with Alexander Schneider

New hope for ovarian cancer, with Alexander Schneider

Alexander Schneider, CEO of CureLab Oncology, shares how his company’s drug candidate for platinum-resistant ovarian cancer is named after his wife.

Biotech is back, with Craig Ackerman

LSX2026: On a therapeutic vision for ocular disease, with Al...

LSX2026: On promise and patience, with Hans Schambye

BIO-Europe Spring 2026: In conversation with Marjorie Sidhou...

Using patient data to fill in GLP-1 blind spots, with Phil J...

JP Morgan 2024 – Katherine Stueland

JP Morgan 2024 – Gene Kinney

JP Morgan 2024 – Frank Gleeson

Biotech is back, with Craig Ackerman

Rewiring commercialisation to meet the moment, with Helen Sa...

STEM AI: Delivering intelligent data-led HCP interactions

Cracking the code: How European biotechs can win in the US m...

BIO-Europe Spring 2026: In conversation with Marjorie Sidhou...

Consolidating data strategy for global success: Insights fro...

Hernexeos and what’s next, with Vicky Brown

A cancer treatment modality that prioritises QoL, with Ben Z...

Engineering “smarter” cells, with Tim Lu

LSX2026: On promise and patience, with Hans Schambye

Using patient data to fill in GLP-1 blind spots, with Phil J...

New hope for ovarian cancer, with Alexander Schneider

LSX2026: On a therapeutic vision for ocular disease, with Al...

BIO-Europe Spring 2026: In conversation with Robert Jacks

Treating the chronic diseases GLP-1s miss, with Laurent Auda...

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Sales & Marketing

Digital

Market Access

Editor's Picks

Oncology

Patients

R&D

Editor's Picks